Our primary objective is to investigate the role of connective tissue growth factor (CTGF, a downstream mediator of profibrotic TGF-β1 activity) in peritoneal fibrosis and EPS. We hypothesize that soluble levels of CTGF and CTGF expression…
ID
Source
Brief title
Condition
- Peritoneal and retroperitoneal conditions
- Renal disorders (excl nephropathies)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The main study parameters are thickness of the peritoneal submesothelial
compact zone, CTGF mRNA and protein expression in the peritoneum, and CTGF
levels in plasma, urine, and peritoneal effluent.
Secondary outcome
The secondary study parameters are the degree of vasculopathy in the
peritoneum, TGF-β1 and VEGF mRNA and protein expression in the peritoneum, and
TGF-β1 and VEGF levels in plasma, urine, and peritoneal effluent.
Background summary
Chronic treatment with peritoneal dialysis (PD) leads to alterations in the
structure of the peritoneal membrane (peritoneal fibrosis). A severe form of
peritoneal fibrosis is encapsulating peritoneal sclerosis (EPS) which has a
high mortality rate. Transforming growth factor β1 (TGF-β1) plays a central
role in peritoneal fibrosis. However, TGF-β1 has several other useful
functions. Therefore, direct inhibition of general TGF-β1 activity is not an
attractive therapeutic option and it remains important to explore the role of
additional growth factors.
Study objective
Our primary objective is to investigate the role of connective tissue growth
factor (CTGF, a downstream mediator of profibrotic TGF-β1 activity) in
peritoneal fibrosis and EPS. We hypothesize that soluble levels of CTGF and
CTGF expression in the peritoneum correlate with the degree and severity of
peritoneal fibrosis.
Study design
Cross-sectional.
Study burden and risks
For this study we need one extra blood collection, urine collection, and a
biopsy of the parietal peritoneum, which will be obtained during the operation.
In patients who are treated by PD a peritoneal equilibration test will be
performed. All procedures will be done during the admission for the kidney
transplantation.
Heidelberglaan 100
3584 CX Utrecht
Nederland
Heidelberglaan 100
3584 CX Utrecht
Nederland
Listed location countries
Age
Inclusion criteria
Patients with ESRD who are about to undergo a kidney transplantation in the University Medical Centre Utrecht.
Exclusion criteria
Patients who are unable to give informed consent.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL23556.041.08 |